| scholarly article | Q13442814 |
| P2093 | author name string | Wei Zhang | |
| M Eileen Dolan | |||
| R Stephanie Huang | |||
| P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
| Human epigenome project--up and running | Q21090247 | ||
| DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project | Q21146392 | ||
| The Sequence of the Human Genome | Q22065842 | ||
| Tumour class prediction and discovery by microarray-based DNA methylation analysis | Q24514903 | ||
| Bisulfite genomic sequencing: systematic investigation of critical experimental parameters | Q24555629 | ||
| A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands | Q24562877 | ||
| Epigenetic modulation of resistance to chemotherapy? | Q80970114 | ||
| DNA methylation and cancer | Q81002014 | ||
| Finding the right dose | Q81419750 | ||
| DNA methylation profiling of human chromosomes 6, 20 and 22 | Q24607522 | ||
| Common genetic variants account for differences in gene expression among ethnic groups | Q24626446 | ||
| Environmental epigenetics and asthma: current concepts and call for studies | Q24654659 | ||
| Global variation in copy number in the human genome | Q24658083 | ||
| A haplotype map of the human genome | Q24679827 | ||
| Epigenetics: environmental instructions for the genome | Q25256980 | ||
| The International HapMap Project | Q27860695 | ||
| Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites | Q28187720 | ||
| Genomic strategies for personalized cancer therapy | Q28251745 | ||
| Environmental exposures and gene regulation in disease etiology | Q28757092 | ||
| Epigenetics in human disease and prospects for epigenetic therapy | Q29547437 | ||
| Relative impact of nucleotide and copy number variation on gene expression phenotypes | Q29614883 | ||
| Population genomics of human gene expression | Q29614905 | ||
| The mammalian epigenome | Q29615763 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Genetic analysis of genome-wide variation in human gene expression | Q29617852 | ||
| Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells | Q29618090 | ||
| A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. | Q30479559 | ||
| Global analysis of genetic, epigenetic and transcriptional polymorphisms in Arabidopsis thaliana using whole genome tiling arrays | Q33325903 | ||
| A genome-wide gene expression signature of environmental geography in leukocytes of Moroccan Amazighs. | Q33327697 | ||
| The DNA methylation paradox | Q33543982 | ||
| Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma | Q34107631 | ||
| A general test of association for quantitative traits in nuclear families | Q34146162 | ||
| MGMT: its role in cancer aetiology and cancer therapeutics | Q34310201 | ||
| High-throughput DNA methylation profiling using universal bead arrays | Q34483135 | ||
| Genome-wide high-resolution mapping and functional analysis of DNA methylation in arabidopsis | Q34562910 | ||
| DNA methylation in health, disease, and cancer | Q34653521 | ||
| Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer | Q34767549 | ||
| Personalized medicine. | Q35069786 | ||
| Epigenomics: beyond CpG islands. | Q35778671 | ||
| High throughput genotyping technologies | Q35828980 | ||
| SNP discovery and typing technologies for pharmacogenomics. | Q35892848 | ||
| Genotyping technologies: application to biotransformation enzyme genetic polymorphism screening. | Q35926561 | ||
| Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach | Q35946327 | ||
| The epigenome as a molecular marker and target | Q36252000 | ||
| Genome-wide identification of genetic determinants for the cytotoxicity of perifosine | Q36475047 | ||
| Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy | Q36477633 | ||
| The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. | Q36528253 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| The role of pharmacogenetics in cancer therapeutics | Q36536674 | ||
| Pharmacogenomics: challenges and opportunities | Q36658763 | ||
| The role of early life genistein exposures in modifying breast cancer risk | Q36667411 | ||
| Evaluation of genetic variation contributing to differences in gene expression between populations | Q36718956 | ||
| Genetic and epigenetic dissection of cis regulatory variation | Q36735903 | ||
| Epigenetic markers and response to chemotherapy in cancer | Q36746204 | ||
| The pharmacogenetics research network: from SNP discovery to clinical drug response. | Q36752662 | ||
| Mining gene expression profiles: expression signatures as cancer phenotypes | Q36868498 | ||
| Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity | Q36966019 | ||
| Genome-wide analysis of DNA methylation patterns | Q36967594 | ||
| Utilization of genomic signatures to direct use of primary chemotherapy | Q37109734 | ||
| Genetic architecture of transcript-level variation in humans | Q37118371 | ||
| Epigenetics of cancer progression | Q37120846 | ||
| Pharmacogenetics: potential role in the treatment of diabetes and obesity | Q37142047 | ||
| Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations | Q37149646 | ||
| Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome | Q37191833 | ||
| Regulation of DNA methylation of Rasgrf1. | Q37373945 | ||
| DNA methylation and epigenetic mechanisms | Q38206837 | ||
| Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. | Q40004108 | ||
| DNA methylation and sensitivity to antimetabolites in cancer cell lines | Q40023657 | ||
| Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. | Q40040939 | ||
| Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. | Q40050705 | ||
| Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines | Q40050748 | ||
| Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. | Q41006885 | ||
| Methylation of promoter proximal-transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex | Q43783313 | ||
| Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines | Q43795492 | ||
| O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma | Q44927043 | ||
| Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | Q46624747 | ||
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity | Q46726161 | ||
| Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome | Q46868712 | ||
| O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells | Q46949370 | ||
| Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. | Q46958965 | ||
| Personalized Medicine: Building the GPS to Take Us There | Q60018444 | ||
| Estimation of DNA Sequence Context-dependent Mutation Rates Using Primate Genomic Sequences | Q62061089 | ||
| DNA modification mechanisms and gene activity during development | Q66907977 | ||
| From genomics to epigenomics: a loftier view of life | Q73238215 | ||
| Epigenomics | Q73504751 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacogenomics | Q1152227 |
| P304 | page(s) | 7-14 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Pharmacogenomics and Personalized Medicine | Q15817568 |
| P1476 | title | Integrating Epigenomics into Pharmacogenomic Studies | |
| P478 | volume | 2008 |
| Q24289309 | Cancer pharmacogenomics: strategies and challenges |
| Q34789161 | Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. |
| Q39983648 | Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression |
| Q33708200 | Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery |
| Q35799841 | Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation |
| Q34157217 | MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits |
| Q36441485 | Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management |
| Q38199010 | Pharmacogenetics of antiplatelet therapy |
| Q42586040 | Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response. |
| Q91829792 | Pharmacogenomics And Hypertension: Current Insights |
| Q36441457 | Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine. |
| Q36441465 | Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine |
| Q42151556 | Prakriti-based medicine: A step towards personalized medicine |
| Q33779644 | SCAN: SNP and copy number annotation |
| Q35599477 | The emerging role of microRNAs in drug responses |
| Q37436398 | Use of cell lines in the investigation of pharmacogenetic loci |
Search more.